The goal of this clinical trial is to learn which procedural intervention most effectively reduces symptoms of chronic rhinitis (non-allergic rhinitis) in adult patients (18 years and older). The main questions it aims to answer are:
* Which procedural intervention leads to the greatest reduction in total nasal symptom scores (TNSS)?
* Which procedural intervention leads to the greatest improvement in sinonasal quality of life as measured by the SNOT-22?
Researchers will compare radiofrequency ablation (RhinAer or Neuromark) and cryotherapy (ClariFix) to see if there are differences in symptom reduction and durability of response across treatments. Participants will:
* Be randomly assigned to one of three FDA-cleared posterior nasal nerve ablation procedures (RhinAer, Neuromark, or ClariFix)
* Complete validated symptom questionnaires (TNSS and SNOT-22) before and after their procedure
* Have their relevant medical records reviewed (demographics, clinical history, prior rhinitis treatments)